✦ LIBER ✦

Factors associated with the suboptimal treatment of women less than 55 years of age with early-stage ovarian cancer

✍ Scribed by John K. Chan; Daniel S. Kapp; Jacob Y. Shin; Kathryn Osann; Gary S. Leiserowitz; Rosemary D. Cress; Cynthia O'Malley

Book ID: 113961343
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 162 KB
Volume: 108
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2007.08.087

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A 3-Year Prospective Study of the Effect

A 3-Year Prospective Study of the Effects of Adjuvant Treatments on Cognition in Women With Early Stage Breast Cancer

✍ Ahles, T.A. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Promoter polymorphism (−786t>C) in the e

Promoter polymorphism (−786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years

✍ Jiachun Lu; Qingyi Wei; Melissa L. Bondy; Tse-Kuan Yu; Donghui Li; Abenaa Brewst 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

Anastrozole is safer and may be more eff

Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer: Abstracted from: Baum M, Buzdar A, Cuzick J, et al. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 2003;98:1802–10

✍ Hetty Carraway; Antonio C. Wolff 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Treatment outcomes in patients less than

Treatment outcomes in patients less than two years of age with small, stage I, favorable-histology Wilms' tumors: A report from the national Wilms' tumor study : D.M. Green, N.E. Breslow, J.B. Beckwith, et al. J Clin Oncol 11:91–95, (January), 1993

✍ Michael P. Hirsh 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 155 KB